Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Georgii

Showing results (121-130 of 138) with videos related to

Pageof 14
Sort By:
Blut|February 1, 1983
Conversion of an IGM secreting immunocytoma in a high grade malignant lymphoma of immunoblastic typeB Emmerich, M Pemsl, I Wüst, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Prognostic value of clinical, laboratory, and histological characteristics in multiple myeloma: improved definition of risk groupsD Peest, R Coldewey, H Deicher, et al.
Pathology, Research and Practice|January 1, 1991
Hyperacute rejection in heart allografts. Case studiesJ Kemnitz, J Cremer, I Restrepo-Specht, et al.
Blood|July 15, 1993
Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study GroupR Hehlmann, H Heimpel, J Hasford, et al.
Leukemia|November 23, 2007
Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromesG Buesche, H Teoman, W Wilczak, et al.
The American Journal of Pathology|March 1, 1997
Lymphocyte-predominant Hodgkin's disease. An immunohistochemical analysis of 208 reviewed Hodgkin's disease cases from the German Hodgkin Study GroupR von Wasielewski, M Werner, R Fischer, et al.
Onkologie|February 1, 1991
[Multicenter prospective controlled study of therapy of chronic myeloid leukemia. Comparison of busulfan, hydroxyurea and interferon alpha (April 1990 status)]R Hehlmann, H Heimpel, B Heinze, et al.
Leukemia|January 1, 1992
Chronic myelogenous leukemia: recent developments in prognostic evaluation and chemotherapy. The German CML Study GroupR Hehlmann, H Heimpel, M Griesshammer, et al.
The American Journal of Pathology|November 5, 1997
Classical Hodgkin's disease. Clinical impact of the immunophenotypeR von Wasielewski, M Mengel, R Fischer, et al.
The Journal of Clinical Endocrinology and Metabolism|July 1, 1995
Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomasG F Scheumman, C Hoang-Vu, Y Cetin, et al.
Pageof 14

Showing results (121-130 of 138) with videos related to

Sort By:
Pageof 14
Blut|February 1, 1983
Conversion of an IGM secreting immunocytoma in a high grade malignant lymphoma of immunoblastic typeB Emmerich, M Pemsl, I Wüst, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Prognostic value of clinical, laboratory, and histological characteristics in multiple myeloma: improved definition of risk groupsD Peest, R Coldewey, H Deicher, et al.
Pathology, Research and Practice|January 1, 1991
Hyperacute rejection in heart allografts. Case studiesJ Kemnitz, J Cremer, I Restrepo-Specht, et al.
Blood|July 15, 1993
Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study GroupR Hehlmann, H Heimpel, J Hasford, et al.
Leukemia|November 23, 2007
Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromesG Buesche, H Teoman, W Wilczak, et al.
The American Journal of Pathology|March 1, 1997
Lymphocyte-predominant Hodgkin's disease. An immunohistochemical analysis of 208 reviewed Hodgkin's disease cases from the German Hodgkin Study GroupR von Wasielewski, M Werner, R Fischer, et al.
Onkologie|February 1, 1991
[Multicenter prospective controlled study of therapy of chronic myeloid leukemia. Comparison of busulfan, hydroxyurea and interferon alpha (April 1990 status)]R Hehlmann, H Heimpel, B Heinze, et al.
Leukemia|January 1, 1992
Chronic myelogenous leukemia: recent developments in prognostic evaluation and chemotherapy. The German CML Study GroupR Hehlmann, H Heimpel, M Griesshammer, et al.
The American Journal of Pathology|November 5, 1997
Classical Hodgkin's disease. Clinical impact of the immunophenotypeR von Wasielewski, M Mengel, R Fischer, et al.
The Journal of Clinical Endocrinology and Metabolism|July 1, 1995
Clinical significance of E-cadherin as a prognostic marker in thyroid carcinomasG F Scheumman, C Hoang-Vu, Y Cetin, et al.
Pageof 14